Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034, ...

The demand for advanced diabetes care goods, including insulin pumps ... The company leverages cutting-edge technologies like ...

CRISPR-Cas9 genome editing exploits the CRISPR-Cas ... pegRNA scaffold incorporation is a common by-product of prime editing, compromising its precision and safety. Here, the authors show that ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

Using gene editing with CRISPR-Cas9, the team has been able to study these proteins without altering ... Dec. 13, 2024 — Microorganisms produce a wide variety of natural products that can be ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

The company’s lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell ...

Civica hired 140 employees in Petersburg last year, began producing insulin products for testing and reached an agreement with a supplier to produce a second type of insulin. Jarvela said the ...

How cardiac cell fates are specified during heart development remains elusive. This study identifies a level-dependent role for transcription factor HAND1 in mesoderm patterning and the specification ...

According to Bloomberg News, the U.S. District Judge Brian Martinotti approved the deal on Tuesday after NVO, among other things, agreed to cap out-of-pocket expenses for its insulin products at $ ...